Basic Information
| LncRNA/CircRNA Name | AGAP2-AS1 |
| Synonyms | NA |
| Region | GRCh38_12:57726271-57728356 |
| Ensemble | ENSG00000255737 |
| Refseq | NR_027032 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Trastuzumab | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, ChIP, RIP, Western blot, Fluorescence in situ hybridization analysis (FISH) |
| Sample | breast cancer tissues, cell lines (SKBR-3, BT474) |
| Expression Pattern | up-regulated |
| Function Description | AGAP2-AS1 was upregulated and transcriptionally induced by SP1 in breast cancer. Overexpression of AGAP2-AS1 promoted cell growth, suppressed apoptosis, and caused trastuzumab resistance. |
| Pubmed ID | 30157918 |
| Year | 2018 |
| Title | SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88. |
External Links
| Links for AGAP2-AS1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |